Compare
Neumora Therapeutics, Inc. vs Vaxart, Inc. vs Instil Bio, Inc. vs Caribou Biosciences, Inc.
| Latest fiscal year | Neumora Therapeutics, Inc. NMRA | Vaxart, Inc. VXRT | Instil Bio, Inc. TIL | Caribou Biosciences, Inc. CRBU |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $237.26M | n/a | $11.16M |
| Revenue growth (YoY) | n/a | +726.7% | n/a | +11.7% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | 7.6% | n/a | n/m |
| Net margin | n/a | 6.9% | n/a | n/m |
| Net income | -$236.93M | $16.33M | -$71.37M | -$148.12M |
| EPS (Diluted) | -$1.45 | $0.07 | -$10.70 | -$1.59 |
| Operating cash flow | -$206.44M | $7.71M | -$36.62M | -$110.99M |
| Free cash flow | n/a | $7.57M | n/a | -$112.35M |
| Cash & equivalents | $182.53M | n/a | $6.64M | $12.36M |
| Total assets | $191.05M | $186.08M | $203.52M | $175.37M |
| Total liabilities | $87.18M | $98.28M | $89.66M | $53.19M |
| Shareholders' equity | $103.87M | $87.80M | $113.87M | $122.17M |
| Return on year-end equity | -228.1% | 18.6% | -62.7% | -121.2% |
| Shares outstanding | 174.26M | 240.49M | 6.78M | 95.14M |
Revenue, most recent five fiscal years
| Fiscal year | Neumora Therapeutics, Inc. | Vaxart, Inc. | Instil Bio, Inc. | Caribou Biosciences, Inc. |
|---|---|---|---|---|
| Latest | n/a | $237.26M Ended 2025-12-31 | $0 Ended 2021-12-31 | $11.16M Ended 2025-12-31 |
| 1 year earlier | n/a | $28.70M Ended 2024-12-31 | $138.0K Ended 2020-12-31 | $9.99M Ended 2024-12-31 |
| 2 years earlier | n/a | $7.38M Ended 2023-12-31 | n/a | $34.48M Ended 2023-12-31 |
| 3 years earlier | n/a | $107.0K Ended 2022-12-31 | n/a | $13.85M Ended 2022-12-31 |
| 4 years earlier | n/a | $892.0K Ended 2021-12-31 | n/a | $9.60M Ended 2021-12-31 |